comprises (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:61, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:62, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:63; and/or wherein the light chain variable region comprises (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:64, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:65, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:66. In some examples, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NOs:2-10; and/or a light chain variable region comprising the amino acid sequence of SEQ ID NOs:16-22. In some examples, the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:61, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:62, and (iii) HVR-H3 comprising the amino acid sequence selected from SEQ ID NOs:67-70; and/or wherein the light chain variable region comprises (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:64, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:65, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:71. In some examples, the antibody comprises a heavy chain variable region comprising the amino acid sequence selected from SEQ ID NOs:11-14; and/or a light chain variable region comprising the amino acid sequence selected from SEQ ID NOs:23-24. In some examples, the antibody comprises a heavy chain variable region comprising the amino acid sequence selected from SEQ ID NOs:2-14; and/or a light chain variable region comprising the amino acid sequence selected from SEQ ID NOs:16-24. In any of the examples herein, the composition may further comprise a pharmaceutically acceptable carrier. In any of the examples herein, the binding affinity and/or binding avidity of the antibody to a human Siglec-8 can be higher than the binding affinity and/or binding avidity of antibody 2E2 or 2C4 to the human Siglec-8. In any of the examples herein, the antibody may have a Tm of at least about 70ºC to at least about 72ºC in a thermal shift assay. In some examples, the antibody has a Tm of about 70ºC, about 71ºC, or about 72ºC. In some examples, the antibody has the same or higher Tm as compared to a chimeric 2C4 antibody. In some examples, the antibody has the same or higher Tm as compared to an antibody having a heavy chain comprising the amino acid sequence of SEQ ID NO:84 and a light chain comprising the amino acid sequence of SEQ ID NO:85.

[0024a] In one aspect, the present disclosure refers to a kit comprising the composition as disclosed herein.

[0024b] In one aspect, the present disclosure refers to the composition as disclosed herein for use in therapy.

[0024c] In one aspect, the present disclosure refers to use of the composition as disclosed herein in the manufacture of a medicament for treating or preventing a disease mediated by cells expressing Siglec-8 in a subject, wherein the disease is selected from the group consisting of: asthma, allergic rhinitis, nasal polyposis, atopic dermatitis, chronic urticaria, mastocytosis, eosinophilic leukemia, hypereosinophilic syndrome, pauci granulocytic asthma, acute or chronic airway hypersensitivity, eosinophilic esophagitis, Churg-Strauss syndrome, inflammation associated with a cytokine, inflammation associated with cells expressing Siglec-8, malignancy associated with cells expressing Siglec-8, physical urticaria, cold urticaria, pressure-urticaria, bullous pemphigoid, food allergy, and allergic bronchopulmonary aspergillosis (ABPA).

[0025] In another example, provided herein is a method of treating or preventing a disease mediated by cells expressing Siglec-8 in a subject, the method comprising administering to the subject an effective amount of an antibody described herein or an antigen-binding fragment thereof or a composition described herein. In some examples, the disease is an eosinophil mediated-disease. In some examples, the disease is a mast cell mediated-disease. In some

CLAIMS

WHAT IS CLAIMED IS:

1. A composition comprising an antibody that specifically binds to human Siglec-8, wherein the antibody comprises a human IgG1 Fc region and N-glycoside-linked carbohydrate chains linked to the Fc region, wherein less than 50% of the N-glycoside-linked carbohydrate chains contain a fucose residue.

2. The composition of claim 1, wherein less than 0.5% of the N-glycoside-linked carbohydrate chains contain a fucose residue.

3. The composition of claim 1 or claim 2, wherein the antibody is a humanized or human antibody.

4. The composition of any one of claims 1-3, wherein the antibody comprises a heavy chain variable region and a light chain variable region, and wherein the heavy chain variable region comprises (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:61, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:62, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:63; and the light chain variable region comprises (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:64, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:65, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:66.

5. The composition of any one of claims 1-3, wherein the antibody comprises a heavy chain variable region and a light chain variable region, and wherein the heavy chain variable region comprises an amino acid sequence selected from SEQ ID NOs:2-10, and the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:16-22.

6. The composition of any one of claims 1-3, wherein the antibody comprises a heavy chain variable region and a light chain variable region, and wherein the heavy chain variable region comprises (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:61, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:62, and (iii) HVR-H3 comprising the amino acid sequence selected from SEQ ID NOs:67-70, and the light chain variable region comprises (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:64, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:65, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:71.

7. The composition of any one of claims 1-3, wherein the antibody comprises a heavy chain variable region and a light chain variable region, and wherein the heavy chain variable region comprises an amino acid sequence selected from SEQ ID NOs:11-14, and the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:23-24.

8. The composition of any one of claims 1-3, wherein the antibody comprises a heavy chain variable region and a light chain variable region, and wherein the heavy chain variable region comprises an amino acid sequence selected from SEQ ID NOs:2-14, and the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:16-24.

9. The composition of any one of claims 1-8, further comprising a pharmaceutically acceptable carrier.

10. The composition of any one of claims 1-9, wherein the antibody has a Tm of at least about 70ºC in a thermal shift assay.

11. The composition of claim 10, wherein the antibody has a Tm of at least about 70ºC to at least about 72ºC in a thermal shift assay.

12. A kit comprising the composition of any one of claims 1-11.

13. The composition of any one of claims 1-11 for use in therapy.

14. Use of the composition of any one of claims 1-11 in the manufacture of a medicament for treating or preventing a disease mediated by cells expressing Siglec-8 in a subject, wherein the disease is selected from the group consisting of: asthma, allergic rhinitis, nasal polyposis, atopic dermatitis, chronic urticaria, mastocytosis, eosinophilic leukemia, hypereosinophilic syndrome, pauci granulocytic asthma, acute or chronic airway hypersensitivity, eosinophilic esophagitis, Churg-Strauss syndrome, inflammation associated with a cytokine, inflammation associated with cells expressing Siglec-8, malignancy associated with cells expressing Siglec-8, physical urticaria, cold urticaria, pressure-urticaria, bullous pemphigoid, food allergy, and allergic bronchopulmonary aspergillosis (ABPA).

15. The use according to claim 14, wherein the composition inhibits one or more symptoms of an allergic reaction.

16. The use according to claim 15, wherein the allergic reaction is a Type I hypersensitivity reaction.

17. The use according to any one of claims 14-16, wherein the subject is suffering from asthma that is not adequately controlled by an inhaled corticosteroid, a short acting β2 agonist, a long acting β2 agonist, or a combination thereof.

18. The use according to any one of claims 14-17, wherein the subject is a human.